Acupuncture in Temporomandibular Disorder Myofascial Pain Treatment: A Systematic Review

2017 ◽  
Vol 31 (3) ◽  
pp. 225-232 ◽  
Author(s):  
Ana Fernandes ◽  
Dayanne Moura ◽  
Laura Da Silva ◽  
Erika De Almeida ◽  
Gustavo Barbosa
2020 ◽  
Vol 2020 ◽  
pp. 1-7
Author(s):  
Emanuela Serritella ◽  
Giordano Scialanca ◽  
Paola Di Giacomo ◽  
Carlo Di Paolo

Several methods are currently used to manage pain related to temporomandibular disorder (TMD). Vibratory stimulation is applied as a pain treatment for several musculoskeletal disorders, but it has not yet been studied in-depth for TMD symptoms. The aim of this study is to analyse the effectiveness of at-home local vibration therapy (LVT) for the management of TMDs-related myofascial pain. Methods. Fifty-four TMD patients (43 F, 11 M) with an average age of 40.7 (age range: 29–54 yr.) were randomly subdivided into two groups. The study group (AG) received 1 week of at-home LVT treatment with the NOVAFON Pro Sk2/2 : 50/100 Hz, bilaterally applied to the pain area for 16 minutes daily. The placebo group (IG) followed the same protocol using inactive devices. Temporomandibular joint pain (TMJ), muscular pain (MM), and headache (HA) were assessed. Pain was evaluated using the visual analogue scale (VAS) before (T0) and after therapy (T1). Statistical analysis and Student’s t-tests were applied (statistical significance for P < 0.05 ). Results. AG patients reported decreased average values for all types of pain considered between T0 and T1, with a statistically significant difference for TMJ pain ( P < 0.05 ), MM pain, and HA ( P < 0.001 ). IG patients reported a no statistically significant decrease in the average values of MM pain and an increase in the average values of TMJ pain and HA. Conclusion. The study supports the use of local vibration therapy in the control of TMD-related TMJ pain, local muscular pain, and headache.


2016 ◽  
Vol 43 (6) ◽  
pp. 468-479 ◽  
Author(s):  
J. Stechman-Neto ◽  
A. L. Porporatti ◽  
I. Porto de Toledo ◽  
Y. M. Costa ◽  
P. C. R. Conti ◽  
...  

2017 ◽  
Vol 10 (16) ◽  
pp. 1-8 ◽  
Author(s):  
Radwan Saleh Algabri ◽  
Ahmed Yaseen Alqutaibi ◽  
Ahmed Mohammed Keshk ◽  
Ali Alsourori ◽  
Mustafa Swedan ◽  
...  

2015 ◽  
Vol 16 (9) ◽  
pp. 1056-1061 ◽  
Author(s):  
Marc Schmitter ◽  
Alexandra Kares-Vrincianu ◽  
Horst Kares ◽  
Justo Lorenzo Bermejo ◽  
Hans-Jürgen Schindler

Pain ◽  
2011 ◽  
Vol 152 (9) ◽  
pp. 2074-2084 ◽  
Author(s):  
Judith A. Turner ◽  
Lloyd Mancl ◽  
Kimberly Hanson Huggins ◽  
Jeffrey J. Sherman ◽  
Gretchen Lentz ◽  
...  

2017 ◽  
Vol 119 (4) ◽  
pp. 775-791 ◽  
Author(s):  
M.L. Fabritius ◽  
C. Strøm ◽  
S. Koyuncu ◽  
P. Jæger ◽  
P.L. Petersen ◽  
...  

10.2196/15309 ◽  
2020 ◽  
Vol 9 (1) ◽  
pp. e15309
Author(s):  
Daenis Camiré ◽  
Jason Erb ◽  
Henrik Kehlet ◽  
Timothy Brennan ◽  
Ian Gilron

Background Postoperative pain is one of the most prevalent and disabling complications of surgery that is associated with personal suffering, delayed functional recovery, prolonged hospital stay, perioperative complications, and chronic postsurgical pain. Accumulating evidence has pointed to the important distinction between pain at rest (PAR) and movement-evoked pain (MEP) after surgery. In most studies including both measures, MEP has been shown to be substantially more severe than PAR. Furthermore, as MEP is commonly experienced during normal activities (eg, breathing, coughing, and walking), it has a greater adverse functional impact than PAR. In a previous systematic review conducted in 2011, only 39% of reviewed trials included MEP as a trial outcome and 52% failed to identify the pain outcome as either PAR or MEP. Given the recent observations of postsurgical pain trials that continue to neglect the distinction between PAR and MEP, this updated review seeks to evaluate the degree of progress in this area. Objective This updated review will include postsurgical clinical trials and meta-analyses in which the primary outcome was early postoperative pain intensity. The primary outcome for this review is the reporting of MEP (vs PAR) as an outcome measure for each trial and meta-analysis. Secondary outcomes include whether trials and meta-analyses distinguished between PAR and MEP. Methods To be consistent with the 2011 review that we are updating, this review will again focus on randomized controlled trials and meta-analyses, from Medical Literature Analysis and Retrieval System Online and EMBASE databases, focusing on pain treatment after thoracotomy, knee arthroplasty, and hysterectomy in humans. Trials and meta-analyses will be characterized as to whether or not they assessed PAR and MEP; whether their pain outcome acknowledged the distinction between PAR and MEP; and, for trials assessing MEP, which pain-evoking maneuver(s) were used. Results Scoping review and pilot data extraction are under way, and the results are expected by March 2020. Conclusions It is our belief that every postsurgical analgesic trial should include MEP as an outcome measure. The previous 2011 review was expected to have an impact on more widespread assessment of MEP in subsequent postoperative pain treatment trials. Thus, the purpose of this follow-up review is to reevaluate the frequency of use of MEP as a trial outcome, compared with PAR, in more recently published postoperative pain trials. Trial Registration PROSPERO CRD42019125855; https://tinyurl.com/qw9dty8 International Registered Report Identifier (IRRID) DERR1-10.2196/15309


2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Aleksandra Nitecka-Buchta ◽  
Piotr Buchta ◽  
Elżbieta Tabeńska-Bosakowska ◽  
Karolina Walczyńska-Dragoń ◽  
Stefan Baron

The aim of the study was the evaluation of myorelaxant action of bee venom (BV) ointment compared to placebo. Parallel group, randomized double blinded trial was performed. Experimental group patients were applying BV for 14 days, locally over masseter muscles, during 3-minute massage. Placebo group patients used vaseline for massage. Muscle tension was measured twice (TON1 and TON2) in rest muscle tonus (RMT) and maximal muscle contraction (MMC) on both sides, right and left, with Easy Train Myo EMG (Schwa-medico, Version 3.1). Reduction of muscle tonus was statistically relevant in BV group and irrelevant in placebo group. VAS scale reduction was statistically relevant in both groups: BV and placebo. Physiotherapy is an effective method for myofascial pain treatment, but 0,0005% BV ointment gets better relief in muscle tension reduction and analgesic effect. This trial is registered with Clinicaltrials.govNCT02101632.


2020 ◽  
Vol 18 (6) ◽  
pp. 741-747
Author(s):  
Silvia Mercedes Coca ◽  
Roberto Ariel Abeldaño Zuñiga

AbstractObjectivePain treatment is an essential component of care for elderly patients with advanced dementia. The objective of this study was to identify and analyze the different scales used for pain assessment in elderly persons diagnosed with dementia, in the literature available at the Latin American level.MethodA systematic review was performed on the existing scales for pain assessment in elderly people diagnosed with Alzheimer's disease, vascular dementia, and dementia with Lewy bodies.Results226 articles were retrieved from the PUBMED, BIREME, and Scielo databases, of which a total of 10 articles entered the systematic review. The instruments identified in these publications were PAINAD, Abbey, McGill, and PACSLAC, while the Colored Pain Scale, Faces Pain Scale, and VAS scales were used as the silver standard. In Spanish, the Abbey scale, and in Portuguese, the PACSLAC scale showed the best reliability and validity coefficients.Significance of resultsIt is concluded that there are only two appropriate scales for the assessment of pain in people with dementia in the region of interest of this study. It is recommended to generate more evidence for a more accurate assessment of pain in people with dementia.


Sign in / Sign up

Export Citation Format

Share Document